Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Feb 6, 2016; 7(1): 107-111
Published online Feb 6, 2016. doi: 10.4292/wjgpt.v7.i1.107
Published online Feb 6, 2016. doi: 10.4292/wjgpt.v7.i1.107
Ref. | Group | UC aggravated | Nausea/vomiting | Headache | Frequent bowel movement | Fatigue | Upper respiratory tract infection | Abdominal pain | Arthralgia | Dizziness | Rash |
Feagan et al[14], 2005 | Placebo | 24 | 15 | 13 | 10 | 7 | 5 | 16 | 5 | 1 | 4 |
0.5 mg/kg IV | 29 | 21 | 12 | 10 | 8 | 8 | 10 | 4 | 6 | 6 | |
2 mg/kg IV | 22 | 13 | 11 | 5 | 5 | 8 | 6 | 7 | 4 | 4 | |
Parikh et al[15], | Placebo | 4 | 1 | 4 | 1 | ||||||
2012 | 2 mg/kg IV | 2 | 2 | 4 | 1 | ||||||
6 mg/kg IV | 1 | 3 | 3 | 0 | |||||||
10 mg/kg IV | 0 | 2 | 1 | 0 | |||||||
Feagan et al[16], 2012 | Placebo | 58 | 19 | 28 | 10 | 21 | 10 | 25 | |||
300 mg IV | 97 | 38 | 80 | 33 | 52 | 35 | 56 |
- Citation: Lau MS, Tsai HH. Review of vedolizumab for the treatment of ulcerative colitis. World J Gastrointest Pharmacol Ther 2016; 7(1): 107-111
- URL: https://www.wjgnet.com/2150-5349/full/v7/i1/107.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i1.107